share_log

敷尔佳(301371.SZ)：拟注销全资子公司北星药业

Fujia (301371.SZ) intends to cancel its wholly-owned subsidiary Beixing Pharmaceutical.

Gelonghui Finance ·  Aug 8 06:54

On August 8th, Gelunhui reported that, in order to further optimize resource allocation, reduce management costs, improve management efficiency and control capabilities, the company held the fourth meeting of the second board of directors on August 8, 2024, and passed the resolution of "About Cancelling the Wholly Owned Subsidiary", which intends to cancel the wholly owned subsidiary of the company, Harbin North Star Pharmaceutical Co., Ltd. (hereinafter referred to as "North Star Pharmaceutical"), and authorize the company's management and related business departments to handle the liquidation and cancellation procedures. The cancellation of North Star Pharmaceutical does not constitute a related transaction, nor does it constitute a major asset restructuring as stipulated in the "Management Measures for Major Asset Restructuring of Listed Companies". This cancellation matter is within the authority of the company's board of directors and does not need to be submitted to the shareholders' meeting for approval.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment